» Articles » PMID: 15896240

Clinical Factors Associated with Hyperkalemia in Patients with Congestive Heart Failure

Overview
Specialties Pharmacology
Pharmacy
Date 2005 May 18
PMID 15896240
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with congestive heart failure (CHF) are at risk for hyperkalemia because of coexisting comorbidities and use of multiple medications that impair potassium (K) excretion such as angiotensin converting enzyme (ACE) inhibitors.

Objective: To identify clinical factors associated with hyperkalemia on initial presentation in patients hospitalized for CHF.

Design: A case-control study.

Setting: Two university-affiliated tertiary-care hospitals.

Subjects: Using ICD-9 code for CHF, CHF admissions with hyperkalemia on presentation (cases) were identified from a population of 938 non-dialysis-dependent CHF patients. CHF admissions with normokalemia on presentation were used as controls. Hyperkalemia was defined as serum K > or = 5.6 mmol/L, and normokalemia as serum K > or = 3.5 and < or =5.5.

Methods: Data were collected on demographic characteristics, clinical variables, comorbidity and medication use. Factors associated with hyperkalemia on initial presentation were examined.

Results: Mean age did not differ between cases [76 years, standard deviation (SD) = 12] and controls (75 years, SD = 12) (P = 0.824). Mean potassium levels for cases and controls were 6.2 mmol/L (range 5.6 to 8.2) and 4.3 mmol/L respectively (P < 0.001). On multivariate analysis, diabetes mellitus [odds ratio (OR) = 2.42, 95% confidence interval (CI) = 1.04-5.59], creatinine clearance <40 mL/min (OR = 8.36, CI = 2.73-25.56), use of spironolactone (OR = 4.18, CI = 1.27-13.79), and use of ACE inhibitors (OR = 2.55, CI = 1.06-6.13) were independently associated with hyperkalemia.

Conclusions: In CHF patients, hyperkalemia on presentation is independently associated with diabetes, creatinine clearance <40 mL/min, use of spironolactone, and use of ACE inhibitors. Recommendations for use of spironolactone and ACE inhibitors in CHF, and the intensity of serum K monitoring need to be clarified to account for patients at higher risk for hyperkalemia.

Citing Articles

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.

Liu Q, Cui Z, Deng C, Yang C, Shi T Front Pharmacol. 2024; 15:1485190.

PMID: 39635439 PMC: 11614654. DOI: 10.3389/fphar.2024.1485190.


Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology.

Pradhan A, Vohra S, Sethi R J Pharm Bioallied Sci. 2021; 12(4):381-390.

PMID: 33679083 PMC: 7909067. DOI: 10.4103/jpbs.JPBS_338_19.


Medication as a risk factor for hospitalization due to heart failure and shock: a series of case-crossover studies in Swiss claims data.

Jodicke A, Burden A, Zellweger U, Tomka I, Neuer T, Roos M Eur J Clin Pharmacol. 2020; 76(7):979-989.

PMID: 32270213 PMC: 7306029. DOI: 10.1007/s00228-020-02835-x.


Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Cooper L, Lippmann S, Greiner M, Sharma A, Kelly J, Fonarow G J Am Heart Assoc. 2017; 6(12).

PMID: 29275368 PMC: 5779000. DOI: 10.1161/JAHA.117.006540.


Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.

Fang G, Annis I, Farley J, Mahendraratnam N, Hickson R, Sturmer T Pharmacotherapy. 2017; 38(1):29-41.

PMID: 29059475 PMC: 5766359. DOI: 10.1002/phar.2051.